Navigation Links
Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
Date:5/5/2008

Presentation Scheduled for Wednesday, May 7th at 9:30am EDT

NEW YORK, May 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 33rd Annual Health Care Conference in Boston, Massachusetts.

Mr. Weiss' presentation, which will take place on Wednesday, May 7th at 9:30am EDT, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell surviva
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Receives Nasdaq Notification
2. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
3. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
4. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
7. Keryx Biopharmaceuticals Announces Additions to Management Team
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
(Date:8/21/2014)... HONG KONG , Aug. 21, 2014  China Cord ... today announced its plan to release financial results for ... August 28, 2014, after market close in the US.  ... call at 8:00 a.m. ET on Friday, August 29, ... brief overview of the Company,s recent developments, followed by ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... , , , SANTA ... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood ... rdblood-amer i ca.com ) focused on bringing ... and internationally, announced today the participation of its subsidiary CorCell ...
... 17, 2009 A UC Irvine center that aims to ... awarded $20 million over five years from the National Science ... of three NSF Centers for Chemical Innovation. Its scientists hope ... single molecules a feat that has proved elusive because ...
... BETHESDA, Md., Aug. 17 Spherix Incorporated (Nasdaq: SPEX ), an ... consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for ... Recent and Upcoming Company Highlights , , ... Clinical trials on Naturlose (D-tagatose) as a treatment ...
Cached Biology Technology:Cord Blood America Announces Preferred Pricing for Blue Cross of Northeastern Pennsylvania Members 2UCI chemistry center awarded $20 million from NSF 2Spherix Reports Second Quarter 2009 Earnings 2Spherix Reports Second Quarter 2009 Earnings 3Spherix Reports Second Quarter 2009 Earnings 4Spherix Reports Second Quarter 2009 Earnings 5Spherix Reports Second Quarter 2009 Earnings 6Spherix Reports Second Quarter 2009 Earnings 7Spherix Reports Second Quarter 2009 Earnings 8
(Date:8/21/2014)... might seem easy to ignore, but they are the ... depend upon. Humans are increasingly dependent on algae, too, ... and sink it to the bottom of the ocean. ... laboratory experiments, researchers have evidence showing that viruses infecting ... algae,s blooms, even when all else stays essentially the ...
(Date:8/21/2014)... food intake, health and quality of life of older ... at the University of Waterloo receiving close to $1.5 ... Research (CIHR). , Professor Heather Keller, of the ... Schlegel research chair in nutrition and aging, will receive ... living in long-term care homes are poorly nourished. The ...
(Date:8/21/2014)... is a key region in the global oceanic circulation. "On ... warm Atlantic water flows to the north into the Arctic ... and sea ice push their way out of the Arctic ... water cools here on its way to the north and ... in this manner drives the global band of oceanic currents ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2Grants will fund landmark aging research at Waterloo 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... treatment and display heightened tumor-generating capacity can be identified by ... cells, a research team led by scientists at The University ... 3 edition of Cell Stem Cell . ... first time to separate low-PSA and high-PSA prostate cancer cells. ...
... Barbara, Calif.) More modest male displays attract the ... sexual selection theory, according to UC Santa Barbara researchers ... May 2 in the open access journal PLoS ... females should find more flamboyant displays the most sexually ...
... one factor that contributes to the overall rising cost ... utilization magnifies the cost burden associated with advanced imaging ... often provide the best clinical information for making a ... number of unnecessary studies are performed. Determining the rate ...
Cached Biology News:Scientists identify prostate cancer stem cells among low-PSA cells 2Scientists identify prostate cancer stem cells among low-PSA cells 3Scientists identify prostate cancer stem cells among low-PSA cells 4UCSB researchers find that less is more, for female cowbirds 2Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports 2
... Magnetofection technology, SilenceMag is the most ... rapid and easy to use, SilenceMag ... Specifically designed for siRNA delivery, SilenceMag ... low doses of siRNA.,SilenceMag formulation gives ...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... contains 400 unique human proteins on ... The proteins, a cross section of ... quadruplicate for high-quality results. Additional control ... guarantee high validity and reproducibility., ,UNIchip ...
Biology Products: